Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine and Fractionated Cisplatin for Muscle Invasive Bladder Cancer
NCT02030574Phase 2Terminated
- Sponsor
- Brown University
- Start
- Jul 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and gemcitabine in Muscle Invasive Bladder Cancer (MIBC) and upper tract urothelial carcinoma (UTUC), sponsored by Brown University. Primary endpoint: Pathologic Complete Response Rate at 6 months. Started Jul 2014; status: terminated.
02
Drugs
cisplatingemcitabine
03
Conditions
Muscle Invasive Bladder Cancer (MIBC)upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT02030574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030574.